Pulkit Chaudhury

Pulkit Chaudhury

Auto-generated profile, based on publicly available information

Pulkit Chaudhury

Cleveland Clinic

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PCPulkit Chaudhury
Pulkit Chaudhury
SGShruti Kumar Gadre
Shruti Kumar Gadre
ESErika Schneider
Erika Schneider
RRRahul D. Renapurkar
Rahul D. Renapurkar
MGMarcelo Gomes
Marcelo Gomes
JBJohn R. Bartholomew
John R. Bartholomew


28 March 2006 in Cell Motility
Verified
Journal Article
Closed access
PDF file
JMJennifer Motil
Jennifer Motil
WCWalter K.-H. Chan
Walter K.-H. Chan
MDMaya Dubey
Maya Dubey
PCPulkit Chaudhury
Pulkit Chaudhury
APAurea Pimenta
Aurea Pimenta
TSThomas B. Shea
Thomas B. Shea

1 January 2012 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GSGayathri Subramanian
Gayathri Subramanian
PCPulkit Chaudhury
Pulkit Chaudhury
KMKrishnakumar Malu
Krishnakumar Malu
SFSamantha Fowler
Samantha Fowler
RMRahul Manmode
Rahul Manmode
PGPeter Charles Wigram Gaines
Peter Charles Wigram Gaines
Lamin B receptor (LBR) is a bifunctional nuclear membrane protein with N-terminal lamin B and chromatin-binding domains plus a C-terminal sterol Δ14 reductase domain. LBR expression increases during neutrophil differentiation, and deficient expression disrupts neutrophil nuclear lobulation characteristic of Pelger-Huët anomaly. Thus, LBR plays a critical role in regulating myeloid differentiation, but how the two functional domains of LBR support this role is currently unclear. We previously identified abnormal proliferation and deficient functional maturation of promyelocytes (erythroid, myeloid, and lymphoid [EML]-derived promyelocytes) derived from EML-ic/ic cells, a myeloid model of ichthyosis (ic) bone marrow that lacks Lbr expression. In this study, we provide new evidence that cholesterol biosynthesis is important to myeloid cell growth and is supported by the sterol reductase domain of Lbr. Cholesterol biosynthesis inhibitors caused growth inhibition of EML cells that increased in EML-derived promyelocytes, whereas cells lacking Lbr exhibited complete growth arrest at both stages. Lipid production increased during wild-type neutrophil maturation, but ic/ic cells exhibited deficient levels of lipid and cholesterol production. Ectopic expression of a full-length Lbr in EML-ic/ic cells rescued both nuclear lobulation and growth arrest in cholesterol starvation conditions. Lipid production also was rescued, and a deficient respiratory burst was corrected. Expression of just the C-terminal sterol reductase domain of Lbr in ic/ic cells also improved each of these phenotypes. Our data support the conclusion that the sterol Δ14 reductase domain of LBR plays a critical role in cholesterol biosynthesis and that this process is essential to both myeloid cell growth and functional maturation.

24 August 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AMAmgad Mentias
Amgad Mentias
MSMarwan Saad
Marwan Saad
MMMadonna Michael
Madonna Michael
SNShady Nakhla
Shady Nakhla
VMVenu Menon
Venu Menon
SKSamir Kapadia
Samir Kapadia
Background: We sought to examine outcomes of direct oral anticoagulants (DOACs) versus warfarin in atrial fibrillation with valve repair/replacement. Methods and Results: Two atrial fibrillation cohorts from Medicare were identified from 2015 to 2019. They comprised patients who underwent surgical or transcatheter mitral valve repair (MV repair cohort) and surgical aortic or mitral bioprosthetic or transcatheter aortic valve replacement (bioprosthetic cohort). Each cohort was divided into warfarin and DOACs (apixaban, rivaroxaban, and dabigatran) groups. Study outcomes included mortality, stroke, and major bleeding. Inverse probability weighting was used for adjustment between the 2 groups in each cohort. The MV repair cohort included 1178 patients. After a median of 468 days, DOACs were associated with lower risk of mortality (hazard ratio [HR], 0.67 [95% CI, 0.55–0.82], P <0.001), ischemic stroke (HR, 0.72 [95% CI, 0.52–1.00], P =0.05) and bleeding (HR, 0.79 [95% CI, 0.63–0.99], P =0.04) compared with warfarin. The bioprosthetic cohort included 8089 patients. After a median follow‐up of 413 days, DOACs were associated with similar risk of mortality (adjusted HR, 0.93 [95% CI, 0.86–1.01], P =0.08), higher risk of ischemic stroke (adjusted HR, 1.27 [95% CI, 1.13–1.43], P <0.001), and lower risk of bleeding (adjusted HR, 0.86 [95% CI, 0.80–0.93], P <0.001) compared with warfarin. Conclusions: In patients with atrial fibrillation, DOACs are associated with similar mortality, lower bleeding, but higher stroke with bioprosthetic valve replacement and lower risk of all 3 outcomes with MV repair compared with warfarin.

10 April 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
BMBrenna McElderry
Brenna McElderry
PAPaulino Alvarez
Paulino Alvarez
MHMazen Hanna
Mazen Hanna
PCPulkit Chaudhury
Pulkit Chaudhury
PBPavan Bhat
Pavan Bhat
AMAmgad Mentias
Amgad Mentias